BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 4094634)

  • 1. [Is aluminum poisoning unavoidable in the uremic patient?].
    Drüeke T; Rottembourg J
    Nephrologie; 1985; 6(5):217-8. PubMed ID: 4094634
    [No Abstract]   [Full Text] [Related]  

  • 2. [Practical considerations on aluminum hazards in uremic patients on dialysis].
    Gilli P; Malacarne F
    Minerva Nefrol; 1982; 29(4):233-4. PubMed ID: 7155444
    [No Abstract]   [Full Text] [Related]  

  • 3. [Aluminium poisoning in uremic children].
    Hinojosa-Lezama M; Gordillo-Paniagua G
    Bol Med Hosp Infant Mex; 1986 Sep; 43(9):532-6. PubMed ID: 3790225
    [No Abstract]   [Full Text] [Related]  

  • 4. Aluminum, vanadium, and lead intoxication of uremic patients undergoing hemodialysis in Venezuela.
    Romero RA
    Transplant Proc; 1994 Feb; 26(1):330-2. PubMed ID: 8109003
    [No Abstract]   [Full Text] [Related]  

  • 5. Iatrogenic aluminum poisoning.
    Savory J
    Clin Chem; 1994 Aug; 40(8):1477-8. PubMed ID: 8044984
    [No Abstract]   [Full Text] [Related]  

  • 6. Dialysis encephalopathy.
    Alfrey AC
    Kidney Int Suppl; 1986 Feb; 18():S53-7. PubMed ID: 3457997
    [No Abstract]   [Full Text] [Related]  

  • 7. Aluminum and iron overload in chronic dialysis.
    Ackrill P; Day JP; Ahmed R
    Kidney Int Suppl; 1988 Mar; 24():S163-7. PubMed ID: 3283407
    [No Abstract]   [Full Text] [Related]  

  • 8. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F; Umetani N; Sato N; Takahashi Y
    J UOEH; 1987 Mar; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients.
    Bakir AA; Hryhorczuk DO; Berman E; Dunea G
    ASAIO Trans; 1986; 32(1):171-6. PubMed ID: 3778707
    [No Abstract]   [Full Text] [Related]  

  • 10. [Osteomalacia as a result of aluminum poisoning during chronic hemodialysis].
    Cournot-Witmer G; Gagnadoux MF; Lebon P; Broyer M; Balsan S
    Arch Fr Pediatr; 1982 Dec; 39 Suppl 2():749-54. PubMed ID: 6762177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aluminum on hematopoiesis.
    Drüeke TB; Lacour B; Touam M; Jucquel JP; Plachot JJ; Cournot-Witmer G; Galle P
    Kidney Int Suppl; 1986 Feb; 18():S45-8. PubMed ID: 3457995
    [No Abstract]   [Full Text] [Related]  

  • 12. [Uremic encephalopathy, dialysis encephalopathy].
    Kinugasa E
    Nihon Rinsho; 2004 Jan; 62 Suppl():424-8. PubMed ID: 15011399
    [No Abstract]   [Full Text] [Related]  

  • 13. [Development of dialysis encephalopathy in the context of rubidium and aluminum levels in the blood and cerebral cortex of patients with concomitant uremic polyneuropathy on long-term dialysis].
    Adamiec R; Uzar J
    Przegl Lek; 1987; 44(3):309-14. PubMed ID: 3615935
    [No Abstract]   [Full Text] [Related]  

  • 14. Aluminum an uremic toxin.
    D'Haese PC; Van de Vyver FL; Lamberts LV; De Broe ME
    Adv Exp Med Biol; 1987; 223():89-96. PubMed ID: 3447454
    [No Abstract]   [Full Text] [Related]  

  • 15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aluminum metabolism.
    Alfrey AC
    Kidney Int Suppl; 1986 Feb; 18():S8-11. PubMed ID: 3458002
    [No Abstract]   [Full Text] [Related]  

  • 17. Aluminum-induced osteomalacia: an explanation.
    Thomas WC; Meyer JL
    Am J Nephrol; 1984; 4(3):201-3. PubMed ID: 6742013
    [No Abstract]   [Full Text] [Related]  

  • 18. Aluminum and renal disease.
    Alfrey AC
    Contrib Nephrol; 1993; 102():110-24. PubMed ID: 8416176
    [No Abstract]   [Full Text] [Related]  

  • 19. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking Al(OH)3.
    Demontis R; Westeel PF; Boudalliez B; Moriniere P; Leflon A; Abdulmassih Z; Atik H; Renaud H; Fournier A
    Kidney Int Suppl; 1988 Mar; 24():S175-7. PubMed ID: 3163043
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of the aluminum overload and of its possible toxicity in asymptomatic uremic patients: evidence for a depressive effect on bone formation.
    Sebert JL; Marie A; Gueris J; Herve MA; Leflon P; Garabedian M; Smadja A; Fournier A
    Bone; 1985; 6(5):373-5. PubMed ID: 4096874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.